Nunzia Pharmaceutical Valuation
| NUNZ Stock | USD 0 0.00 0.00% |
Nunzia Pharmaceutical seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Nunzia Pharmaceutical from analyzing the firm fundamentals such as Shares Outstanding of 434.52 M, return on asset of -2702.39, and EBITDA of (9.02 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Nunzia Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Nunzia Pharmaceutical is based on 3 months time horizon. Increasing Nunzia Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nunzia Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nunzia Pink Sheet. However, Nunzia Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.003 | Real 0.00252 | Hype 0.003 | Naive 0.003 |
The intrinsic value of Nunzia Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nunzia Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nunzia Pharmaceutical helps investors to forecast how Nunzia pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nunzia Pharmaceutical more accurately as focusing exclusively on Nunzia Pharmaceutical's fundamentals will not take into account other important factors: Nunzia Pharmaceutical Total Value Analysis
Nunzia Pharmaceutical is now estimated to have valuation of 87.59 M with market capitalization of 24.88 M, debt of 139.96 K, and cash on hands of 5.07 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nunzia Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
87.59 M | 24.88 M | 139.96 K | 5.07 K |
Nunzia Pharmaceutical Asset Utilization
One of the ways to look at asset utilization of Nunzia is to check how much profit was generated for every dollar of assets it reports. Nunzia Pharmaceutical secures a negative usage of assets of -2702.39 %, losing $27.02 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Nunzia Pharmaceutical shows how discouraging it operates for each dollar spent on its assets.Nunzia Pharmaceutical Ownership Allocation
Nunzia Pharmaceutical maintains a total of 434.52 Million outstanding shares. Nunzia Pharmaceutical secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 81.95 % of Nunzia Pharmaceutical outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nunzia Pharmaceutical Profitability Analysis
Net Loss for the year was (9.02 M) with profit before overhead, payroll, taxes, and interest of 0.About Nunzia Pharmaceutical Valuation
Our relative valuation model uses a comparative analysis of Nunzia Pharmaceutical. We calculate exposure to Nunzia Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nunzia Pharmaceutical's related companies.Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California. Nunzia Pharmaceutical is traded on OTC Exchange in the United States.
8 Steps to conduct Nunzia Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Nunzia Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nunzia Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Nunzia Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Nunzia Pharmaceutical's revenue streams: Identify Nunzia Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Nunzia Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Nunzia Pharmaceutical's growth potential: Evaluate Nunzia Pharmaceutical's management, business model, and growth potential.
- Determine Nunzia Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nunzia Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Nunzia Pharmaceutical Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 284.9 M | |
| Retained Earnings | -9.4 M | |
| Retained Earnings Total Equity | -179.4 M |
Additional Tools for Nunzia Pink Sheet Analysis
When running Nunzia Pharmaceutical's price analysis, check to measure Nunzia Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nunzia Pharmaceutical is operating at the current time. Most of Nunzia Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Nunzia Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nunzia Pharmaceutical's price. Additionally, you may evaluate how the addition of Nunzia Pharmaceutical to your portfolios can decrease your overall portfolio volatility.